Shared Decision Making and Renal Supportive Care
SDMRSC
1 other identifier
interventional
172
1 country
1
Brief Summary
This year, 90,000 Americans with end-stage renal disease (ESRD) will die and questions will legitimately be raised as to whether terminal treatment and location of death adequately represented their preferences. These concerns are linked by a failure on the part of patients and staff to discuss prognosis and share in end-of-life (EOL) planning. The rate of hospice use among patients dying with ESRD is half that of the national average and one-quarter the rate for patients with terminal cancer. In other patient populations when meaningful EOL conversation occurs this is associated with increased hospice referral and improved quality of the dying. Patients receiving hemodialysis (HD) often desire but rarely communicate with staff about prognoses, know little about availability of community hospice resources, or how to complete advance directives. Nephrologists are not trained to have these conversations, and although accustomed to relying on interdisciplinary teams, they are unaccustomed to collaborating with community hospices. Our preliminary research began by using focus groups, created and validated the first clinically useful HD prognostic tool, and developed a prototype for Shared Decision Making and Renal Supportive Care (SDM-RSC). This is a novel multimodal intervention that familiarizes patients, families, and dialysis staff with community hospice resources, emphasizes dialysis social work support, conveys information about terminal care issues, and encourages advance care planning. The proposed study tests the central hypothesis that EOL care can be improved by relying on patients and stakeholders to enhance SDM-RSC for HD patients who are most likely to die. It will test whether an intervention that targets communication deficiencies can alter EOL outcomes and achieve the goal of matching patient preferences with terminal treatments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2014
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2014
CompletedFirst Submitted
Initial submission to the registry
February 6, 2015
CompletedFirst Posted
Study publicly available on registry
April 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedJuly 6, 2017
July 1, 2017
2.5 years
February 6, 2015
July 3, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
hospice use (documented in administrative data)
Hospice use as documented in administrative data
2 years prior to study initiation to 1 year post initiation
Secondary Outcomes (4)
location of death (site of death (home) as documented in administrative data)
12 months post enrollment
completion of advanced directives (documented in administrative data)
12 months post enrollment
depressive symptoms (Patient Health Questionnaire-9 Scores)
Change from baseline over 12 months of follow-up or until subject death, whichever came first
Caregiver Satisfaction (Famcare Scores)
Change from baseline over 12 months of follow-up or until subject death, whichever came first
Study Arms (1)
advance care planning
EXPERIMENTALnephrologist empowers social worker to meet with patient and family.
Interventions
patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
Eligibility Criteria
You may qualify if:
- High-risk patients, as defined by falling within the high-risk category of our validated prognostic instrument and have approximately 50% 18-month mortality.
- English- and Spanish-speaking patients will be included (estimated to be 95% of this population).
- Patients who receive hemodialysis at one of our 16 research dialysis sites during the data collection period.
- Patients must be willing and able to sign the consent form.
- Patients who are lack the capacity to meaningfully participate in medical decisions must have a surrogate who is willing to sign the informed consent.
You may not qualify if:
- Children 18 years of age. Children constitute 2% of the dialysis population, and our preliminary survey of the study sites found no children were active patients. In any case, the renal and other physical factors of children with ESRD are not directly comparable to those of adults.
- Does not belong to the population's high-mortality risk quintile according to our prognostic instrument
- Severe psychiatric disorders including schizophrenia, bipolar disorder which would interfere with participation in the study (severity determined by psychiatric hospitalization in the past month or actively suicidal)
- Active substance abuse (active abuse is defined as using alcohol or recreational drugs in the past 30 days in a way that interferes with their ability to function in daily life)
- Expectation of native kidney recovery
- History of poor adherence to thrice-weekly hemodialysis (poor adherence defined by missing 4 treatments in the past month)
- Unable to communicate in English or Spanish
- Scheduled for living donor kidney transplant, conversion to peritoneal dialysis, or plans to relocate to another hemodialysis unit
- Current pregnancy or actively planning to become pregnant
- Currently a prisoner
- Unable or unwilling to follow the study protocol
- Unable or unwilling to provide informed consent or sign Institutional Review Board (IRB)-approval or lack of a surrogate/proxy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Baystate Medical Centerlead
- University of New Mexicocollaborator
- Northeastern Universitycollaborator
- Patient-Centered Outcomes Research Institutecollaborator
Study Sites (1)
Fresenius Medical Corporation Dialysis Clinics
Springfield, Massachusetts, 01199, United States
Related Publications (2)
Goff SL, Unruh ML, Klingensmith J, Eneanya ND, Garvey C, Germain MJ, Cohen LM. Advance care planning with patients on hemodialysis: an implementation study. BMC Palliat Care. 2019 Jul 26;18(1):64. doi: 10.1186/s12904-019-0437-2.
PMID: 31349844DERIVEDEneanya ND, Goff SL, Martinez T, Gutierrez N, Klingensmith J, Griffith JL, Garvey C, Kitsen J, Germain MJ, Marr L, Berzoff J, Unruh M, Cohen LM. Shared decision-making in end-stage renal disease: a protocol for a multi-center study of a communication intervention to improve end-of-life care for dialysis patients. BMC Palliat Care. 2015 Jun 12;14:30. doi: 10.1186/s12904-015-0027-x.
PMID: 26066323DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lewis Cohen, MD
Baystate Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Psychiatrist
Study Record Dates
First Submitted
February 6, 2015
First Posted
April 1, 2015
Study Start
September 1, 2014
Primary Completion
March 1, 2017
Study Completion
March 1, 2017
Last Updated
July 6, 2017
Record last verified: 2017-07